Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Protein Phosphatase 2A (PP2A or EC Market Report - Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 07 Dec 17

The "Protein Phosphatase 2A (PP2A or EC - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

'Protein Phosphatase 2A - Pipeline Review, H2 2017'; Protein Phosphatase 2A (PP2A or EC pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.

Protein Phosphatase 2A (PP2A or EC - Protein Phosphatase 2A (PP2A) is an enzyme encoded by the PPP2CA gene. PP2A plays important roles in regulation of cell cycle, signal transduction, cell differentiation, and transformation. Its activity is related to several diseases, including neurodegenerative diseases and cancer.

The report 'Protein Phosphatase 2A - Pipeline Review, H2 2017' outlays comprehensive information on the Protein Phosphatase 2A (PP2A or EC targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Key Topics Covered:

  1. Introduction
  2. Protein Phosphatase 2A (PP2A or EC - Overview
  3. Protein Phosphatase 2A (PP2A or EC - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Protein Phosphatase 2A (PP2A or EC - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Protein Phosphatase 2A (PP2A or EC - Companies Involved in Therapeutics Development
  • Ampio Pharmaceuticals Inc
  • Cyano Biotech GmbH
  • Lixte Biotechnology Holdings Inc
  • PEP-Therapy SAS
  • Re-Pharm Ltd
  • Signum Biosciences Inc

For more information about this report visit

View source version on

Business Wire

Last updated on: 07/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.